On May 15, 2026, the Fourth Shenzhen International Academic Conference on Safety and Health Testing Technologies, alongside the 2026 Greater Bay Area Collaboration and Promotion Event for Scientific Instruments and Laboratory Technology Industries, was held in Shenzhen. Professor Wang Jianxun, Chief Scientist and Co-founder of Shenzhen Cell Valley Biopharmaceutical Group Co., Ltd., was invited to attend and delivered a keynote speech titled "Development Trends in the Cell Therapy Industry Following the Implementation of State Council Decree No. 818: Regulations on the Administration of Clinical Research and Clinical Translational Application of Emerging Biomedical Technologies." In his address, he provided a detailed analysis of policy dividends and development opportunities, highlighted Shenzhen Cell Valley's core technological advantages, and drew enthusiastic recognition and high praise from the attending experts and scholars.

The conference focused on innovations in safety and health testing technologies and the coordinated development of science and technology industries across the Greater Bay Area, bringing together top experts, industry leaders, and corporate representatives from biomedicine, precision instrumentation, laboratory technology, and related fields. It served as a premier platform for academic exchange, technology matchmaking, and industrial cooperation, supporting the high-quality development of the life and health industry in the Guangdong-Hong Kong-Macao Greater Bay Area. As a core frontier of biomedicine, cell therapy was one of the key areas highlighted at the conference.

In his speech, Professor Wang Jianxun systematically interpreted the core principles and industrial value of State Council Decree No. 818, the *Regulations on the Administration of Clinical Research and Clinical Translational Application of Emerging Biomedical Technologies*. He noted that the promulgation of Decree No. 818 clarifies, at the national level, the legal status and regulatory pathway for emerging biomedical technologies, including cell therapy—marking a milestone in the standardized, high-quality development of the industry. The regulations streamline clinical research processes through a filing system, clarify the rights and responsibilities of all parties, and standardize pathways for translational application, encouraging technological innovation while reinforcing safety oversight throughout the process. Professor Wang emphasized that rigorous regulation is not a constraint but rather a "protective shield" for the healthy development of the industry. It effectively eliminates non-compliant practices, cleanses the industrial environment, provides broad development space for enterprises with genuine technical strength and compliance capabilities, and drives the cell therapy industry from a phase of "unregulated growth" toward a new stage of "standardized high-quality development."

As a pioneering scientist in the industrial-scale production of retroviral vectors in China, Professor Wang Jianxun highlighted Shenzhen Cell Valley's core technological advantages and industrial strategy. The company has been deeply engaged in the full industrial chain of cell and gene therapy and is among the first service platforms in China with GMP industrial-scale production capabilities for clinical-grade retroviral vectors. Leveraging its proprietary retroviral vector and engineered eVLP pseudoviral vector technologies, the company has addressed critical bottlenecks in the industry.

Professor Wang Jianxun stated that Shenzhen Cell Valley is driven by the mission "Cells benefit all, genes create the future," empowering the industry with advanced technologies. The company has already established a full-process service system covering technology R&D, pilot production, and clinical translation, fully aligned with the requirements of Decree No. 818 for the clinical research and translational application of emerging biomedical technologies. Looking ahead, Shenzhen Cell Valley will further leverage its technology platform advantages to build a specialized cell product manufacturing platform, deeply empower hospital-based clinical research and translational application, assist medical institutions in rapidly conducting compliant and efficient cell therapy technology research, and work together to bring cell therapy technologies to more patients, contributing core strength to the innovative development of China's biomedical industry.

Professor Wang Jianxun's keynote speech not only showcased Shenzhen Cell Valley's technological strength and industry commitment in the cell and gene therapy field but also clearly outlined the development blueprint for the cell therapy industry under Decree No. 818. Moving forward, Shenzhen Cell Valley will continue to deepen core technology innovation, strengthen industry-academia-research-medicine collaboration, seize policy opportunities, support the high-quality development of the cell therapy industry in the Greater Bay Area and nationwide, and write a new chapter in the clinical translation of emerging biomedical technologies.